Liminatus Pharma, Inc. 8-K

What Happened
Liminatus Pharma, Inc. (Nasdaq: LIMN) announced on May 20, 2026 that it entered into a Merger Agreement dated May 17, 2026 to acquire InnocsAI LLC. Under the agreement InnocsAI will merge into a new, wholly owned Delaware subsidiary of Liminatus (Merger Sub); the agreement calls for issuing 1,600,000,000 shares of Liminatus common stock at $0.20 per share (the “Closing Payment Shares”) plus contingent value rights representing the right to receive 20% of net proceeds from any future strategic sale, out-license, transfer, or exit of the acquired assets. The merger is subject to customary closing conditions, stockholder/member approvals and a termination backstop of December 31, 2026.

Key Details

• Consideration: 1,600,000,000 shares at $0.20 per share (implied value $320 million) plus CVRs equal to 20% of net proceeds from future strategic monetization of acquired assets.
• Pipeline acquired: oncology-focused biologic and cellular therapy programs, including IBC101 (autologous CD19xCD22 bivalent CAR‑T; Phase 1/2a authorization in South Korea for relapsed/refractory DLBCL), INC101/INC102 (preclinical dual‑antigen CAR‑T designs for solid tumors, with INC102 armored against TGF‑β), and a CS1 antibody platform aimed at extending CAR‑T targeting into plasma‑cell malignancies.
• Related‑party note: Valetudo Therapeutics LLC is a member of InnocsAI; Chris Kim, Liminatus’s CEO and director, is CEO and controlling member of Valetudo.
• Corporate/process items: Liminatus will file an SEC registration statement and proxy/prospectus to register the Closing Payment Shares and solicit stockholder approval; closing is conditioned on regulatory and stockholder approvals and customary reps/covenants.

Why It Matters
This is a material strategic transaction: if completed, Liminatus would issue a very large number of shares (1.6B), which could significantly dilute existing shareholders and materially change the company’s asset and clinical profile by adding CAR‑T and antibody programs. The deal expands Liminatus’s pipeline into both hematologic and solid‑tumor immunotherapies (including a program already cleared for a Phase 1/2a study in Korea), but it is subject to stockholder approval, regulatory clearances, fulfillment of closing conditions, and clinical and development risks. Investors should note the related‑party connection involving the CEO and that the transaction is not final until closing and related filings and votes are completed.